Finance

Lists
Why is KYTX up 5,18%?
Dive Deeper
KYTX:NASDAQ
Kyverna Therapeutics Inc
6,50 US$
+5,18%
(+0,32) 1D
9 ოქტ, 14:55:02 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for KYTX...
Open
6,20 US$
High
6,58 US$
Low
6,18 US$
Mkt. cap
401,98 მლნ.
Avg. vol.
906,89 ათ.
Volume
567,23 ათ.
52-wk high
13,67 US$
52-wk low
5,96 US$
EPS
-2,94 US$
Shares outstanding
61,84 მლნ.
No. of employees
149
Open
6,20 US$
High
6,58 US$
Low
6,18 US$
Mkt. cap
401,98 მლნ.
Avg. vol.
906,89 ათ.
Volume
567,23 ათ.
52-wk high
13,67 US$
52-wk low
5,96 US$
EPS
-2,94 US$
Shares outstanding
61,84 მლნ.
No. of employees
149
News stories
From web sources and news partners
Stock Traders Daily
Stock Traders Daily
·
1 დღის წინ
(KYTX) Movement as an Input in Quant Signal Sets
About Kyverna Therapeutics Inc
CEO-
Employees149
Founded2018
HeadquartersEmeryville, კალიფორნია, ამერიკის შეერთებული შტატები
Sector-
Analyst ratings
Based on 4 analysts giving stock ratings to KYTX in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for KYTX in the last 3 months.
Highest
Current 6,50 US$
33,00 US$ (+407,69%)
Average
30,33 US$ (+366,62%)
Lowest
25,00 US$ (+284,62%)
Analyst
Recommendation
Action
Price target
Projected
Date
Mitchell Kapoor
H.C. Wainwright
Buy
Reiterated
25,00 US$
+284,6%
09/25/2026
Derek Archila
Wells Fargo
Buy
Reiterated
33,00 US$
+407,7%
09/25/2026
Matt Phipps
William Blair
Buy
Maintained
-
-
09/24/2026
Michael Ulz
Morgan Stanley
Buy
Reiterated
33,00 US$
+407,7%
08/12/2026
Sami Corwin
William Blair
Buy
Maintained
-
-
08/12/2026
Brian Cheng
J.P. Morgan
Buy
Reiterated
29,00 US$
+346,2%
05/13/2026
Unknown Analyst
J.P. Morgan
Buy
Maintained
30,00 US$
+361,5%
03/30/2026
Last report
11 აგვ. 2026
Fiscal period
Q2 2026
-0,63 US$ / -0,68 US$
+7,28%beat
Revenue / Est. (USD)
- / 0,00
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
-
-
-
-
Cost of goods sold
30,46 მლნ.
-103,71 მლნ.
30,07 მლნ.
-
Cost of revenue
30,46 მლნ.
-103,71 მლნ.
30,07 მლნ.
-
Research and development expenses
-
133,72 მლნ.
-
24,79 მლნ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
8,27 მლნ.
9,27 მლნ.
11,29 მლნ.
14,77 მლნ.
Operating expense
8,27 მლნ.
142,99 მლნ.
11,29 მლნ.
39,56 მლნ.
Total operating expenses
38,73 მლნ.
39,28 მლნ.
41,37 მლნ.
39,56 მლნ.
Operating income
-38,73 მლნ.
-39,28 მლნ.
-41,37 მლნ.
-39,56 მლნ.
Other non operating income
-53,00 ათ.
17,00 ათ.
-21,00 ათ.
-18,00 ათ.
EBT including unusual items
-36,79 მლნ.
-37,80 მლნ.
-39,73 მლნ.
-38,32 მლნ.
EBT excluding unusual items
-36,79 მლნ.
-37,80 მლნ.
-39,73 მლნ.
-38,32 მლნ.
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-36,79 მლნ.
-37,80 მლნ.
-39,73 მლნ.
-38,32 მლნ.
Net profit margin
-
-
-
-
Earnings per share
-0,85
-0,80
-0,66
-0,63
Interest and investment income
2,00 მლნ.
1,90 მლნ.
2,33 მლნ.
1,93 მლნ.
Interest expense
-7,00 ათ.
-444,00 ათ.
-667,00 ათ.
-674,00 ათ.
Net interest expenses
1,99 მლნ.
1,46 მლნ.
1,66 მლნ.
1,26 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
-37,84 მლნ.
-38,91 მლნ.
-41,02 მლნ.
-39,12 მლნ.
Gain or loss from assets sale
40,00 ათ.
20,00 ათ.
-
-47,00 ათ.
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google აპები